Portal de Periódicos da CAPES

Comparative effects of therapeutic programs on bovine respiratory disease, performance, carcass, and profitability of high-risk feedlot heifers

2013; Elsevier BV; Volume: 29; Issue: 3 Linguagem: Inglês

10.15232/s1080-7446(15)30226-6

1525-318X

J. E. Stegner, Martín Lucas, C. L. McLaughlin, Michael S. Davis, G. R. Alaniz, Daniel J. Weigel, John H. Pollreisz, Cassius M. Tucker, W. C. Koers, O. A. Turgeon, J. I. Szasz,

Plant Pathogenic Bacteria Studies

Two therapeutic programs were compared in heifers at high risk for bovine respiratory disease (BRD) during a 208d feeding period.Program 1 [metaphylactic tulathromycin followed by as-needed use of ceftiofur crystalline free acid, after a 14-d postmetaphylactic interval (PMI; treatment moratorium); T01] was compared with program 2 [metaphylactic tilmicosin phosphate followed by as-needed use of enrofloxacin, after a 3-d PMI (treatment moratorium); T02].Auctionsourced heifers (n = 1,236; initial BW = 258 ± 2.1 kg) were randomized to treatment [T01, n = 620; T02, n = 616; 8 pens/treatment] and processed.Rates of BRD (10.3 vs. 26.0%;P = 0.0001), BRD re-treatment (1.6 vs. 6.3%;P = 0.0001), and G:F [0.27 vs. 0.24, deads in (P = 0.004); 0.28 vs. 0.27, deads out (P = 0.099)] were improved during the initial 70 d for T01 versus T02 heifers, respectively, but not during d 71 to 208.Medicine costs ($2.56 vs. $7.90/heifer; P < 0.0001), cost of gain (deads-in basis: $2.07 vs. $2.16/kg; P = 0.086), and profitability ($21.43 vs. -$2.55/heifer;P = 0.0935) were significantly improved for T01 versus T02 heifers, respectively.For high-risk cattle, a therapeutic program consisting of metaphylactic treatment with tulathromycin followed by use of ceftiofur crystalline free acid as a standard feedlot therapy, after a 14-d PMI, compared with a second program consisting of metaphylactic tilmicosin phosphate followed by enrofloxacin, after a 3-d PMI, significantly reduced the incidences of both initial and re-treated BRD, thereby improving G:F, medicine costs, cost of gain (deads in), and profitability.